Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Share-based Compensation: 2012-2025

Historic Share-based Compensation for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $4.0 million.

  • Enanta Pharmaceuticals' Share-based Compensation fell 47.73% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 30.71%. This contributed to the annual value of $18.6 million for FY2025, which is 30.71% down from last year.
  • Enanta Pharmaceuticals' Share-based Compensation amounted to $4.0 million in Q3 2025, which was down 3.42% from $4.2 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Share-based Compensation high stood at $8.1 million for Q4 2023, and its period low was $4.0 million during Q3 2025.
  • Moreover, its 3-year median value for Share-based Compensation was $5.7 million (2024), whereas its average is $6.0 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Share-based Compensation spiked by 38.87% in 2022, and later plummeted by 47.73% in 2025.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Share-based Compensation stood at $6.1 million in 2021, then grew by 17.77% to $7.1 million in 2022, then grew by 13.45% to $8.1 million in 2023, then plummeted by 30.04% to $5.7 million in 2024, then tumbled by 47.73% to $4.0 million in 2025.
  • Its Share-based Compensation was $4.0 million in Q3 2025, compared to $4.2 million in Q2 2025 and $4.7 million in Q1 2025.